Syndax Pharmaceuticals (SNDX) Common Equity (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Common Equity of $41.6 million for Q1 2026, down 80.65% year-over-year from $215.1 million in Q1 2025, and down 35.6% quarter-over-quarter from $64.6 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Common Equity (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Common Equity history runs 12 years deep, the most recent figure standing at $41.6 million for Q1 2026.
- In Q1 2026, Common Equity fell 80.65% year-over-year to $41.6 million; the TTM figure through Mar 2026 stood at $41.6 million (down 80.65% YoY), while the FY2025 annual figure was $64.6 million, down 77.57% from the prior year.
- Common Equity for Q1 2026 stood at $41.6 million, down from $64.6 million in the prior quarter.
- The five-year high for Common Equity was $554.2 million in Q4 2023, with the low at $41.6 million in Q1 2026.
- The 5-year median for Common Equity is $361.9 million (2022), against an average of $321.5 million.
- The sharpest annual moves came in 2022 and 2026: Common Equity soared 69.9% in 2022, then sank 80.65% in 2026.
- Syndax Pharmaceuticals' Common Equity stood at $467.4 million in 2022, then climbed by 18.56% to $554.2 million in 2023, then plunged by 48.01% to $288.1 million in 2024, then sank by 77.57% to $64.6 million in 2025, then plunged by 35.6% to $41.6 million in 2026.
- Business Quant data shows SNDX's Common Equity at $41.6 million in Q1 2026, $64.6 million in Q4 2025, and $115.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 15.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.10 Mn |
| Mar 31, 2026 | 41.62 Mn |
| Dec 31, 2025 | 64.63 Mn |
| Sep 30, 2025 | 115.43 Mn |
| Jun 30, 2025 | 157.42 Mn |
| Mar 31, 2025 | 215.06 Mn |
| Dec 31, 2024 | 288.12 Mn |
| Sep 30, 2024 | 366.43 Mn |
| Jun 30, 2024 | 434.34 Mn |
| Mar 31, 2024 | 491.89 Mn |
| Dec 31, 2023 | 554.20 Mn |
| Sep 30, 2023 | 359.19 Mn |
| Jun 30, 2023 | 400.04 Mn |
| Mar 31, 2023 | 435.51 Mn |
| Dec 31, 2022 | 467.45 Mn |
| Sep 30, 2022 | 338.10 Mn |
| Jun 30, 2022 | 361.94 Mn |
| Mar 31, 2022 | 374.55 Mn |
| Dec 31, 2021 | 408.37 Mn |
| Sep 30, 2021 | 199.00 Mn |